Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data

Abstract

Introduction

Conventional pharmaceutical interventions for inflammatory bowel disease (IBD) provide limited disease/symptom control and are associated with an increased risk of adverse events (AEs). These limitations increase patient morbidity, medical resource utilization (MRU), and costs.

Methods

The IQVIA™ Real-World Data Adjudicated Claims–US database was leveraged to identify adult patients (> 18 years) with Crohn’s disease (Crohn’s) or ulcerative colitis (UC), who were new and chronic users (≥ 60 days) of oral corticosteroids (OCS), immunosuppressants (IS), anti-tumor necrosis factor agents (anti-TNF) or combinations thereof. Using aminosalicylate-treated patients as a reference, we compared AE incidence, MRU, and medical costs across drug classes.

Results

The analysis included 30,676 patients (Crohn’s: n = 14,528; UC: n  = 16,148). OCS monotherapy was the strongest predictor of any AE occurring [Crohn’s: hazard ratio 1.62 (1.51–1.73); UC: hazard ratio 1.57 (1.49–1.66)]. A similar pattern was observed for severe infection and bone-related conditions. Patients with UC or Crohn’s receiving OCS or IS plus OCS were more likely to have emergency department visits, IBD-related hospitalizations/visits/procedures, and gastrointestinal surgery than were patients receiving other therapies. Annualized total medical costs (pharmacy plus hospital service costs) were greatest for anti-TNF plus IS or anti-TNF therapy in both Crohn’s and UC. Annualized medical service costs (excluding IBD drug costs) were highest for patients initiating OCS-containing therapies [Crohn’s: OCS, $27,041 (24,882–29,200) and OCS plus IS, $23,332 (19,889–26,775); UC: OCS, $19,659 (17,977–21,340)].

Conclusion

Although biologic therapies have higher pharmacy costs, treatment decisions should consider the increased AE risks and long-term MRU costs associated with chronic use of OCS-containing therapies.

Funding

This study was funded by F. Hoffmann-La Roche Ltd. The journal’s Rapid Service Fee and Open Access publication were paid for by ApotheCom on behalf of Genentech, a member of the Roche group who funded the study.

Electronic Supplementary Material

The online version of this article (10.1007/s12325-019-01095-1) contains supplementary material, which is available to authorized users.